These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34927520)

  • 1. Real-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: a retrospective analysis of electronic medical data from community cancer care providers.
    Epstein RS; Weerasinghe RK; Parrish AS; Krenitsky J; Sanborn RE; Salimi T
    J Med Econ; 2022; 25(1):108-118. PubMed ID: 34927520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Burden of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer: A retrospective study from community oncology practices.
    Hart L; Ogbonnaya A; Boykin K; Deyoung K; Bailey R; Heritage T; Lopez-Gonzalez L; Huang H; Gordan L
    Cancer Med; 2023 Apr; 12(8):10020-10030. PubMed ID: 37000119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression: Results from an Online Survey of Patients with Solid Tumors.
    Epstein RS; Aapro MS; Basu Roy UK; Salimi T; Krenitsky J; Leone-Perkins ML; Girman C; Schlusser C; Crawford J
    Adv Ther; 2020 Aug; 37(8):3606-3618. PubMed ID: 32642965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Burden of chemotherapy-induced myelosuppression among patients with ES-SCLC in US community oncology settings.
    Goldschmidt J; Monnette A; Shi P; Venkatasetty D; Lopez-Gonzalez L; Huang H
    Future Oncol; 2022 Nov; 18(35):3881-3894. PubMed ID: 36377828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns and burden of myelosuppression for patients with small cell lung cancer: A SEER-medicare study.
    Epstein RS; Nelms J; Moran D; Girman C; Huang H; Chioda M
    Cancer Treat Res Commun; 2022; 31():100555. PubMed ID: 35421820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of myelosuppression on quality of life of patients treated with chemotherapy.
    Crawford J; Herndon D; Gmitter K; Weiss J
    Future Oncol; 2024; 20(21):1515-1530. PubMed ID: 38587388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials.
    Ferrarotto R; Anderson I; Medgyasszay B; García-Campelo MR; Edenfield W; Feinstein TM; Johnson JM; Kalmadi S; Lammers PE; Sanchez-Hernandez A; Pritchett Y; Morris SR; Malik RK; Csőszi T
    Cancer Med; 2021 Sep; 10(17):5748-5756. PubMed ID: 34405547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy.
    Abraham I; Onyekwere U; Deniz B; Moran D; Chioda M; MacDonald K; Huang H
    J Med Econ; 2021 Nov; 24(sup1):71-83. PubMed ID: 34873975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States.
    Abraham I; Goyal A; Deniz B; Moran D; Chioda M; MacDonald KM; Huang H
    J Manag Care Spec Pharm; 2022 Apr; 28(4):435-448. PubMed ID: 35100006
    [No Abstract]   [Full Text] [Related]  

  • 10. Survival, Chemotherapy Treatments, and Health Care Utilization Among Patients with Advanced Small Cell Lung Cancer: An Observational Study.
    He J; Shao C; Hui SL; Zhang Z; Baker J; Dexter PR; Kachroo S; Jin F
    Adv Ther; 2020 Jan; 37(1):552-565. PubMed ID: 31828610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Advances in Supportive Care: Chemoprotective Agents as Novel Opportunities in Geriatric Oncology.
    Balducci L; Falandry C; List A
    Curr Oncol Rep; 2022 Dec; 24(12):1695-1703. PubMed ID: 35986858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy.
    Goldschmidt J; Hart L; Scott J; Boykin K; Bailey R; Heritage T; Lopez-Gonzalez L; Zhou ZY; Edwards ML; Monnette A; Ogbonnaya A; Deyoung K; Venkatasetty D; Shi P; Aton L; Huang H; Conkling PR; Gordan L
    Adv Ther; 2023 Oct; 40(10):4189-4215. PubMed ID: 37490258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy treatments, costs of care, and survival for patients diagnosed with small cell lung cancer: A SEER-Medicare study.
    Shao C; He J; Kachroo S; Jin F
    Cancer Med; 2019 Dec; 8(18):7613-7622. PubMed ID: 31668011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world utilization of immune checkpoint inhibitors in extensive stage small-cell lung cancer in community settings.
    Zu K; Arunachalam A; Hohlbauch A; Silver M; Robert N
    Immunotherapy; 2023 Nov; 15(16):1375-1387. PubMed ID: 37694560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health outcomes and healthcare resource utilization among Veterans with stage IV non-small cell lung cancer treated with second-line chemotherapy versus immunotherapy.
    Williams CD; Allo MA; Gu L; Vashistha V; Press A; Kelley M
    PLoS One; 2023; 18(2):e0282020. PubMed ID: 36809528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis.
    Ito D; Feng C; Fu C; Kim C; Wu J; Epstein J; Snider JT; DuVall AS
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):773-787. PubMed ID: 37278284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study.
    Hart LL; Ferrarotto R; Andric ZG; Beck JT; Subramanian J; Radosavljevic DZ; Zaric B; Hanna WT; Aljumaily R; Owonikoko TK; Verhoeven D; Xiao J; Morris SR; Antal JM; Hussein MA
    Adv Ther; 2021 Jan; 38(1):350-365. PubMed ID: 33123968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving Outcomes of Chemotherapy: Established and Novel Options for Myeloprotection in the COVID-19 Era.
    Lyman GH; Kuderer NM; Aapro M
    Front Oncol; 2021; 11():697908. PubMed ID: 34307165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics and Healthcare Burden of Patients with Schizophrenia Treated in a US Integrated Healthcare System.
    Mahabaleshwarkar R; Lin D; Joshi K; Fishman J; Blair T; Hetherington T; Palmer P; Patel C; Krull C; Tcheremissine OV
    J Ment Health Policy Econ; 2021 Jun; 24(2):47-59. PubMed ID: 34151777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
    Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
    Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.